U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H21NO8S
Molecular Weight 339.3636
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOPIRAMATE

SMILES

CC1(C)O[C@]2([H])CO[C@]3(COS(=O)(=O)N)[C@]([H])([C@]2([H])O1)OC(C)(C)O3

InChI

InChIKey=KJADKKWYZYXHBB-XBWDGYHZSA-N
InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1

HIDE SMILES / InChI

Molecular Formula C12H21NO8S
Molecular Weight 339.3636
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020505s055,020844s046lbl.pdf

Topiramate is an anticonvulsant indicated in the treatment of epilepsy and migraine. Topiramate enhances GABA-activated chloride channels. In addition, topiramate inhibits excitatory neurotransmission, through actions on kainate and AMPA receptors. There is evidence that topiramate has a specific effect on GluR5 kainate receptors. It is also an inhibitor of carbonic anhydrase, particular subtypes II and IV, but this action is weak and unlikely to be related to its anticonvulsant actions, but may account for the bad taste and the development of renal stones seen during treatment. Its possible effect as a mood stabilizer seems to occur before anticonvulsant qualities at lower dosages. Topiramate inhibits maximal electroshock and pentylenetetrazol-induced seizures as well as partial and secundarily generalized tonic-clonic seizures in the kindling model, findings predective of a broad spectrum of antiseizure activities clinically. The precise mechanism of action of topiramate is not known. However, studies have shown that topiramate blocks the action potentials elicited repetitively by a sustained depolarization of the neurons in a time-dependent manner, suggesting a state-dependent sodium channel blocking action. Topiramate also augments the activity of the neurotransmitter gamma-aminobutyrate (GABA) at some subtypes of the GABAAreceptor (controls an integral chloride channel), indicating a possible mechanism through potentiation of the activity of GABA. Topiramate also demonstrates antagonism of the AMPA/kainate subtype of the glutamate excitatory amino acid receptor. It also inhibits carbonic anhydrase (particularly isozymes II and IV), but this action is weak and unlikely to be related to its anticonvulsant actions. Topiramate is used for the treatment and control of partial seizures and severe tonic-clonic (grand mal) seizures and also for the prevention of migraine headaches. In children it is also used for treatment of Lennox-Gastaut syndrome. Topiramate is sold under the brand name Topamax. A combination product containing phentermine and topiramate extended-release called QSYMIA® is indicated for the management of obesity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
5.0 nM [Ki]
4.9 µM [Ki]
0.9 nM [Ki]
3.8 nM [Ki]
63.0 nM [Ki]
30.0 nM [Ki]
47.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TOPAMAX

Approved Use

TOPAMAX is indicated for: Monotherapy epilepsy: Initial monotherapy in patients > 2 years of age with partial onset or primary generalized tonic-clonic seizures Adjunctive therapy epilepsy: Adjunctive therapy for adults and pediatric patients (2 to 16 years of age) with partial onset seizures or primary generalized tonic-clonic seizures, and in patients >2 years of age with seizures associated with Lennox-Gastaut syndrome (LGS) Migraine: Treatment for adults and adolescents 12 years of age and older for prophylaxis of migraine headache

Launch Date

8.5129921E11
Preventing
TOPAMAX

Approved Use

TOPAMAX is indicated for: Monotherapy epilepsy: Initial monotherapy in patients > 2 years of age with partial onset or primary generalized tonic-clonic seizures Adjunctive therapy epilepsy: Adjunctive therapy for adults and pediatric patients (2 to 16 years of age) with partial onset seizures or primary generalized tonic-clonic seizures, and in patients >2 years of age with seizures associated with Lennox-Gastaut syndrome (LGS) Migraine: Treatment for adults and adolescents 12 years of age and older for prophylaxis of migraine headache

Launch Date

8.5129921E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.98 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
8 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.46 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
1.63 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18.38 μg/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
28.73 μg/mL
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.68 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
350.3 mg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
311.2 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
57.3 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
59.8 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18.7 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
22 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
20 h
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
23 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOPIRAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
59%
unknown, unknown
TOPIRAMATE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg 1 times / day steady, oral
MTD
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
healthy, 23.3 years (range: 20–26 years)
n = 8
Health Status: healthy
Age Group: 23.3 years (range: 20–26 years)
Sex: M+F
Population Size: 8
Sources:
4000 mg single, oral
Overdose
Dose: 4000 mg
Route: oral
Route: single
Dose: 4000 mg
Sources:
unknown, 24 years
n = 1
Health Status: unknown
Age Group: 24 years
Sex: F
Population Size: 1
Sources:
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 6-15 years
n = 77
Health Status: unhealthy
Condition: Epilepsy
Age Group: 6-15 years
Population Size: 77
Sources:
Disc. AE: Attention concentration difficulty, Fever...
AEs leading to
discontinuation/dose reduction:
Attention concentration difficulty (>=2)
Fever (>=2)
Flushing (>=2)
Confusion (>=2)
Sources:
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, >16 years
n = 159
Health Status: unhealthy
Condition: Epilepsy
Age Group: >16 years
Population Size: 159
Sources:
Disc. AE: Memory impairment, Fatigue...
AEs leading to
discontinuation/dose reduction:
Memory impairment (>=2)
Fatigue (>=2)
Asthenia (>=2)
Insomnia (>=2)
Somnolence (>=2)
Paresthesia (>=2)
Sources:
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
Disc. AE: Psychomotor retardation, Memory impairment...
AEs leading to
discontinuation/dose reduction:
Psychomotor retardation (4%)
Memory impairment (3.2%)
Fatigue (3.2%)
Confusion (3.1%)
Somnolence (3.2%)
Attention concentration difficulty (2.9%)
Anorexia (2.7%)
Depression (2.6%)
Dizziness (2.5%)
Weight decrease (2.5%)
Nervousness (2.3%)
Ataxia (2.1%)
Paresthesia (2%)
Sources:
30 mg/kg 1 times / day steady, oral
Dose: 30 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg/kg, 1 times / day
Sources:
unhealthy, pediatric (<16 years)
n = 310
Health Status: unhealthy
Condition: epilepsy
Age Group: pediatric (<16 years)
Population Size: 310
Sources:
Disc. AE: Convulsions aggravated, Attention concentration difficulty...
AEs leading to
discontinuation/dose reduction:
Convulsions aggravated (2.3%)
Attention concentration difficulty (1.6%)
Language disorder (1.3%)
Personality disorder (1.3%)
Somnolence (1.3%)
Sources:
96 g single, oral
Overdose
unknown
n = 1
Other AEs: Coma...
AEs

AEs

AESignificanceDosePopulation
Attention concentration difficulty >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 6-15 years
n = 77
Health Status: unhealthy
Condition: Epilepsy
Age Group: 6-15 years
Population Size: 77
Sources:
Confusion >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 6-15 years
n = 77
Health Status: unhealthy
Condition: Epilepsy
Age Group: 6-15 years
Population Size: 77
Sources:
Fever >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 6-15 years
n = 77
Health Status: unhealthy
Condition: Epilepsy
Age Group: 6-15 years
Population Size: 77
Sources:
Flushing >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 6-15 years
n = 77
Health Status: unhealthy
Condition: Epilepsy
Age Group: 6-15 years
Population Size: 77
Sources:
Asthenia >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, >16 years
n = 159
Health Status: unhealthy
Condition: Epilepsy
Age Group: >16 years
Population Size: 159
Sources:
Fatigue >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, >16 years
n = 159
Health Status: unhealthy
Condition: Epilepsy
Age Group: >16 years
Population Size: 159
Sources:
Insomnia >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, >16 years
n = 159
Health Status: unhealthy
Condition: Epilepsy
Age Group: >16 years
Population Size: 159
Sources:
Memory impairment >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, >16 years
n = 159
Health Status: unhealthy
Condition: Epilepsy
Age Group: >16 years
Population Size: 159
Sources:
Paresthesia >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, >16 years
n = 159
Health Status: unhealthy
Condition: Epilepsy
Age Group: >16 years
Population Size: 159
Sources:
Somnolence >=2
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, >16 years
n = 159
Health Status: unhealthy
Condition: Epilepsy
Age Group: >16 years
Population Size: 159
Sources:
Paresthesia 2%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
Ataxia 2.1%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
Nervousness 2.3%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
Dizziness 2.5%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
Weight decrease 2.5%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
Depression 2.6%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
Anorexia 2.7%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
Attention concentration difficulty 2.9%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
Confusion 3.1%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
Fatigue 3.2%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
Memory impairment 3.2%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
Somnolence 3.2%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
Psychomotor retardation 4%
Disc. AE
1400 mg 1 times / day steady, oral
Highest studied dose
Dose: 1400 mg, 1 times / day
Route: oral
Route: steady
Dose: 1400 mg, 1 times / day
Sources:
unhealthy, adult (>16 years)
n = 1757
Health Status: unhealthy
Condition: epilepsy
Age Group: adult (>16 years)
Sex: M+F
Population Size: 1757
Sources:
Language disorder 1.3%
Disc. AE
30 mg/kg 1 times / day steady, oral
Dose: 30 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg/kg, 1 times / day
Sources:
unhealthy, pediatric (<16 years)
n = 310
Health Status: unhealthy
Condition: epilepsy
Age Group: pediatric (<16 years)
Population Size: 310
Sources:
Personality disorder 1.3%
Disc. AE
30 mg/kg 1 times / day steady, oral
Dose: 30 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg/kg, 1 times / day
Sources:
unhealthy, pediatric (<16 years)
n = 310
Health Status: unhealthy
Condition: epilepsy
Age Group: pediatric (<16 years)
Population Size: 310
Sources:
Somnolence 1.3%
Disc. AE
30 mg/kg 1 times / day steady, oral
Dose: 30 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg/kg, 1 times / day
Sources:
unhealthy, pediatric (<16 years)
n = 310
Health Status: unhealthy
Condition: epilepsy
Age Group: pediatric (<16 years)
Population Size: 310
Sources:
Attention concentration difficulty 1.6%
Disc. AE
30 mg/kg 1 times / day steady, oral
Dose: 30 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg/kg, 1 times / day
Sources:
unhealthy, pediatric (<16 years)
n = 310
Health Status: unhealthy
Condition: epilepsy
Age Group: pediatric (<16 years)
Population Size: 310
Sources:
Convulsions aggravated 2.3%
Disc. AE
30 mg/kg 1 times / day steady, oral
Dose: 30 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg/kg, 1 times / day
Sources:
unhealthy, pediatric (<16 years)
n = 310
Health Status: unhealthy
Condition: epilepsy
Age Group: pediatric (<16 years)
Population Size: 310
Sources:
Coma 1 patient
96 g single, oral
Overdose
unknown
n = 1
PubMed

PubMed

TitleDatePubMed
Developments in mood stabilisers.
2001
Cutaneous drug reaction case reports: from the world literature.
2001
Comparative efficacy and tolerability of drug treatments for bipolar disorder.
2001
Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy.
2001
Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications.
2001
The management of refractory idiopathic epilepsies.
2001
Management strategies for refractory localization-related seizures.
2001
Topiramate in posttraumatic stress disorder: preliminary clinical observations.
2001
The new generation of GABA enhancers. Potential in the treatment of epilepsy.
2001
Cognitive side effects of anticonvulsants.
2001
Auditory hallucinations associated with topiramate.
2001 Aug
Confusion and dysphoria with low-dose topiramate in a patient with bipolar disorder.
2001 Aug
Newer antiepileptic drugs: advantages and disadvantages.
2001 Aug
Uveal effusion and secondary angle-closure glaucoma associated with topiramate use.
2001 Aug
First break of mania associated with topiramate treatment.
2001 Aug
Topiramate in venlafaxine-induced visual hallucinations in an obese patient with a posterior cerebral artery infarction.
2001 Aug
Panic attacks associated with the use of topiramate.
2001 Aug
Intrinsic optical signals and electrographic seizures in the rat limbic system.
2001 Dec
Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy.
2001 Dec
Topiramate selectively attenuates nicotine-induced increases in monoamine release.
2001 Dec 1
Effect of tiagabine and topiramate on porphyrin metabolism in an in vivo model of porphyria.
2001 Jul
The role of new antiepileptic drugs.
2001 Jul
Incoercible topiramate-related vomiting in a patient with epilepsy and mental retardation.
2001 Jun
Topiramate for self-mutilation in a patient with borderline personality disorder.
2001 Jun
Topiramate abuse in a bipolar patient with an eating disorder.
2001 Jun
Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design.
2001 Jun
[Social and economic aspects of administration of new antiepileptic drugs].
2001 Mar-Apr
Clinical experience with topiramate dosing and serum levels in children 12 years or under with epilepsy.
2001 Nov
Bilateral angle-closure glaucoma and ciliary body swelling from topiramate.
2001 Nov
National survey on West syndrome in Korea.
2001 Nov
Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation.
2001 Nov
Hypohidrosis related to the administration of topiramate to children.
2001 Oct
Topiramate-induced metabolic acidosis: report of two cases.
2001 Oct
Plasma concentration of topiramate correlates with cerebrospinal fluid concentration.
2001 Oct
Quetiapine-related tardive dyskinesia.
2001 Oct
Topiramate-induced depression.
2001 Oct
Drug-resistant cluster headache responding to gabapentin: a pilot study.
2001 Sep
[Topiramate: an experience in children with partial epilepsy].
2001 Sep
Re: Weight change with antipsychotic use.
2001 Sep
Postmarketing experience with topiramate and cognition.
2001 Sep
Topiramate for headaches.
2001 Sep
Weight loss with topiramate.
2001 Sep
Topiramate blocks perinatal hypoxia-induced seizures in rat pups.
2001 Sep
Topiramate as a mood stabilizer.
2001 Sep
Topiramate on ictal seizure semiology: a quantitative, randomized, low and medium dose-controlled study.
2001 Sep
Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma.
2001 Sep 15
Topiramate as a neuroprotectant in a rat model of global ischemia-induced neurodegeneration.
2001 Sep 28
Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication.
2001 Sep-Oct
Clinical and electroencephalographic effects of topiramate in patients with epilepsy and healthy volunteers.
2001 Sep-Oct
Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder.
2001 Sep-Oct
Patents

Sample Use Guides

Recommended dose: 400 mg orally per day in 2 divided doses of 200 mg each The dose should be achieved by titration: Week 1: 25 mg orally in the morning and 25 mg orally in the evening Week 2: 50 mg orally in the morning and 50 mg orally in the evening Week 3: 75 mg orally in the morning and 75 mg orally in the evening Week 4: 100 mg orally in the morning and 100 mg orally in the evening Week 5: 150 mg orally in the morning and 150 mg orally in the evening Week 6: 200 mg orally in the morning and 200 mg orally in the evening
Route of Administration: Oral
0.3 to 10 uM topiramate 1 inhibited ATPA-evoked postsynaptic currents recorded from rat basolateral amygdala (BLA) interneurons
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:50:58 UTC 2021
Edited
by admin
on Fri Jun 25 20:50:58 UTC 2021
Record UNII
0H73WJJ391
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TOPIRAMATE
HSDB   INCI   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN   INCI  
Official Name English
TOPIRAMATE [USP-RS]
Common Name English
USL-255
Code English
TOPIRAMATE [USP MONOGRAPH]
Common Name English
TOPIRAMATE [WHO-DD]
Common Name English
TPM
Common Name English
TOPINA
Brand Name English
TOPOMAX
Brand Name English
TOPAMAX
Brand Name English
TOPIRAMATE [USAN]
Common Name English
TOPIRAMATE [JAN]
Common Name English
QUDEXY
Brand Name English
TOPIRAMATE [EP MONOGRAPH]
Common Name English
EPITOMA
Brand Name English
TOPIRAMATE [VANDF]
Common Name English
TOPIMAX
Brand Name English
EPITOMAX
Brand Name English
SINCRONIL
Brand Name English
TOPIRAMATE [USP]
Common Name English
TOPIRAMATE [MART.]
Common Name English
TOPIRAMATE COMPONENT OF QSYMIA
Brand Name English
TOPIRAMATE [INCI]
Common Name English
TOPIRAMATE [MI]
Common Name English
USL255
Code English
.BETA.-D-FRUCTOPYRANOSE, 2,3:4,5-BIS-O-(1-METHYLETHYLIDENE)-, SULFAMATE
Common Name English
TOPIRAMATE [HSDB]
Common Name English
TOPIRAMATE [INN]
Common Name English
RWJ-17021-000
Code English
MCN-4853
Code English
RWJ-17021
Code English
QSYMIA COMPONENT TOPIRAMATE
Brand Name English
TOPIRAMATE [ORANGE BOOK]
Common Name English
(-)-TOPIRAMATE
Common Name English
2,3:4,5-DI-O-ISOPROPYLIDENE-.BETA.-D-FRUCTOPYRANOSE SULFAMATE
Common Name English
TOPAMAC
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C264
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
WHO-ATC N03AX11
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
FDA ORPHAN DRUG 283909
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
NDF-RT N0000008486
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
NDF-RT N0000175753
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
WHO-VATC QN03AX11
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
LIVERTOX 981
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
FDA ORPHAN DRUG 70792
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
EMA ASSESSMENT REPORTS QSIVA (REFUSED: OBESITY)
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
Code System Code Type Description
NDF-RT
N0000182140
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY Cytochrome P450 2C19 Inhibitors [MoA]
CAS
97240-79-4
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
HSDB
7531
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
DRUG CENTRAL
2706
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
USP_CATALOG
1672206
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY USP-RS
FDA UNII
0H73WJJ391
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
WIKIPEDIA
TOPIRAMATE
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
LACTMED
Topiramate
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
ChEMBL
CHEMBL220492
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
MERCK INDEX
M10976
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY Merck Index
IUPHAR
6849
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
NDF-RT
N0000185506
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY Cytochrome P450 3A4 Inducers [MoA]
INN
6099
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
EPA CompTox
97240-79-4
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
PUBCHEM
5284627
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
NCI_THESAURUS
C47764
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
MESH
C052342
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
RXCUI
38404
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY RxNorm
EVMPD
SUB11190MIG
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
DRUG BANK
DB00273
Created by admin on Fri Jun 25 20:50:58 UTC 2021 , Edited by admin on Fri Jun 25 20:50:58 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
BINDER->LIGAND
decreases as concentration increases
BINDING
TARGET -> AGONIST
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
EXCRETED UNCHANGED
URINE
Related Record Type Details
METABOLITE -> PARENT
MINOR
URINE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC